Authors: Konecny, G Untch, M Arboleda, J Wilson, C Kahlert, S Boettcher, B Felber, M Beryt, M Lude, S Hepp, H Slamon, D Pegram, M

Citation: G. Konecny et al., HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer, CLIN CANC R, 7(8), 2001, pp. 2448-2457

Authors: Konecny, G Fritz, M Untch, M Lebeau, A Felber, M Lude, S Beryt, M Hepp, H Slamon, D Pegram, M

Citation: G. Konecny et al., HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer, BREAST CANC, 69(1), 2001, pp. 53-63

Authors: Konecny, G Untch, M Slamon, D Beryt, M Kahlert, S Felber, M Langer, E Lude, S Hepp, H Pegram, M

Citation: G. Konecny et al., Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples, BREAST CANC, 67(3), 2001, pp. 223-233

Authors: Lackey, DB Groziak, MP Sergeeva, M Beryt, M Boyer, C Stroud, RM Sayre, P Park, JW Johnston, P Slamon, D Shepard, HM Pegram, M

Citation: Db. Lackey et al., Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase, BIOCH PHARM, 61(2), 2001, pp. 179-189

Authors: Pegram, M Hsu, S Lewis, G Pietras, R Beryt, M Sliwkowski, M Coombs, D Baly, D Kabbinavar, F Slamon, D

Citation: M. Pegram et al., Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, ONCOGENE, 18(13), 1999, pp. 2241-2251